Stryker Stock Testing Price Floor – Buy Now?
Stryker (SYK) stock should be on your watchlist. Here is why – it is currently trading in the support zone ($279.99 – $309.47), levels from which it has bounced meaningfully before. Since it first started trading, Stryker stock received buying interest at this level 3 times and subsequently went on to generate 17.7% in average peak returns.
| Peak Return | Days to Peak Return | |
|---|---|---|
| 1/24/2024 | 16.8% | 63 |
| 4/19/2024 | 7.4% | 48 |
| 8/5/2024 | 28.9% | 354 |
Yet, a support zone alone isn’t enough; rebounds are more likely when fundamentals, sentiment, and market conditions line up. How does that look for SYK?
Rebound Likely: Cyber Impact Temporary, Strong Fundamentals
Stryker’s Q1 EPS and revenue missed expectations due to a March cyberattack, leading to recent stock pressure and analyst target reductions. However, management reaffirmed full-year 2026 guidance, indicating the disruption is temporary. The stock trades significantly below analyst consensus targets, appearing undervalued with strong underlying profitability and growth metrics. Industry tailwinds like increasing demand for medical devices, advancements in AI, and surgical robotics, including Stryker’s Mako platform, underpin a positive outlook. A rebound is probable as operational recovery progresses and robust market trends prevail.
- Salesforce Stock Can Sink, Here Is How
- Is Philip Morris International Stock Undervalued Stock Or Value Trap?
- Is LLY Stock Setup For A Rerating?
- Is Tenet Healthcare Stock an Under-Analyzed Capital Compounder Opportunity?
- 5 Catalysts to Monitor Over In The Next 2 Quarters For LLY Stock
- Could Accenture Stock’s Cash Flow Spark the Next Rally?
How Do SYK Financials Look Right Now?
- Revenue Growth: 11.2% LTM and 10.8% last 3-year average.
- Cash Generation: Nearly 17.1% free cash flow margin and 20.1% operating margin LTM.
- Recent Revenue Shocks: The minimum annual revenue growth in the last 3 years for SYK was 10.2%.
- Valuation: SYK stock trades at a PE multiple of 34.7
| SYK | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Health Care Equipment | – |
| PE Ratio | 34.7 | 24.4 |
|
|
||
| LTM* Revenue Growth | 11.2% | 6.9% |
| 3Y Average Annual Revenue Growth | 10.8% | 5.6% |
| Min Annual Revenue Growth Last 3Y | 10.2% | 0.8% |
|
|
||
| LTM* Operating Margin | 20.1% | 18.5% |
| 3Y Average Operating Margin | 20.0% | 18.2% |
| LTM* Free Cash Flow Margin | 17.1% | 14.2% |
*LTM: Last Twelve Months | For more details on SYK fundamentals, read Buy or Sell SYK Stock.
And What If The Support Breaks?
Stryker isn’t immune to big sell-offs either. It fell about 59% in the Global Financial Crisis and around 44% during the Covid plunge. The Dot-Com Bubble and Inflation Shock also saw dips close to 36% and 32%, respectively. Even the smaller 2018 correction wiped out nearly 19% from its peak. Strong fundamentals matter, but when panic hits, deep pullbacks happen—even for solid stocks like Stryker.
But the risk is not limited to major market crashes. Stocks fall even when markets are in good shape – think events like earnings, business updates, outlook changes. Read SYK Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.
Still not sure about SYK stock? Consider the portfolio approach.
Portfolios Win When Stock Picks Fall Short
Single stocks swing wildly, but staying invested matters. A well-built portfolio helps you stay invested, captures upside, and softens the blows from individual stocks.
Why settle for average market returns? The Trefis High Quality (HQ) Portfolio invests in a diverse group of 30 stocks that have collectively delivered stronger upside with reduced volatility compared to the broader indices. Discover the methodology behind these smoother, higher returns by checking the HQ Portfolio performance data.